Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL10P7 is a processed pseudogene, meaning it originated from retrotransposition of mRNA from a functional ribosomal protein L10 gene (RPL10), but has lost its protein-coding ability and is generally not transcribed or translated into a functional protein[2][3][4]. The RPL10 gene encodes a structural protein in the large 60S subunit of ribosomes, important for protein synthesis[1][5]. However, RPL10P7 and similar pseudogenes are non-functional genomic relics without known physiological or pathological significance[2][4]. Multiple RPL10 pseudogenes exist in the human genome, but only the original (RPL10) and certain paralogs (like RPL10L) encode active proteins with biological functions[3][4][6]. No evidence supports RPL10P7 as a drug target, disease-related biomarker, or functional participant in cellular processes. If the query intended a functional protein target (such as RPL10 or RPL10L), those have specific roles in ribosome structure and function, but RPL10P7 does not. The naming similarity often causes confusion, so attention is required to select the correct gene/protein in research or therapeutic contexts.
None (no drug mechanism as not a target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ribosomal protein L10 pseudogene 7 (RPL10P7).